The impact of pulse pressure to manage the antihypertensive differential therapy;Pulse pressure in der therapiestieuerung der hypertonie?

Herz

Volumn 29, Issue 3, 2004, Pages 276-289

  Scholze, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antihypertensive differential therapy; Hypertension; Isolated systolic hypertension; Pulse pressure epidemiology, pathophysiology and treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CILAZAPRIL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; ISRADIPINE; LISINOPRIL; LONG ACTING DRUG; NEBIVOLOL; NIFEDIPINE; NITRATE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; ANTIHYPERTENSIVE AGENT;

ACUTE HEART INFARCTION; AGING; CARDIOVASCULAR RISK; CHRONIC VEIN INSUFFICIENCY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DYSLIPIDEMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE EJECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; KIDNEY FAILURE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; PULSE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRANSIENT ISCHEMIC ATTACK; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE; CLASSIFICATION; DRUG EFFECT; METHODOLOGY; PATIENT CARE; RISK ASSESSMENT; RISK FACTOR;

AGE DISTRIBUTION; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PATIENT CARE MANAGEMENT; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 2642548297     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2550-z     Document Type: Review

References (89)

1. Asmar R, Benetos A, Brahimi M, et al. Arterial and hypertensive effects of nitrendipine: a double-blind comparison versus placebo. J Cardiovasc Pharmacol 1992;20:858-63.
2. Asmar RG. Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus. JRAAS 2001;2:Suppl 2:S8-11.
3. Asmar RG. Pulse pressure. An important tool in cardiovascular pharmacology. Drugs 2003;63:927-32.
4. Asmar RG, London GM, O'Rourke ME, et al. Improvement in blood pressure, arterial stiffness and wave reflection with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001;38:922-6.
5. Asmar RG, Vol S, Brisac AM, et al. Reference values for clinic pulse pressure in a nonselected population. Am J Hypertens 2001;14:415-8.
6. Bakker ENTP, van der Meulen ET, van den Berg BM, et al. Inward remodeling follows chronic vasoconstriction in isolated resistance arteries. J Vasc Res 2002;39:12-20.
7. Benetos A, Zureik M, Morcet J, et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with high cardiovascular mortality. J Am Coll Cardiol 2000;35:673-80.
8. Blacher J, Gasowski J, Staessen JA, et al. Pulse pressure, not mean pressure, determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160:1085-9.
9. Breithaupt-Grogler K, Leschinger M, Belz GG, et al. Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Cardiovasc Drugs Ther 1996;10:49-57.
10. Chau NP, Simon A, Vijar J, et al. Active and passive effects of antihypertensive drugs on large artery diameter and elasticity in human essential hypertension. J Cardiovasc Pharmacol 1992;19:78-85.
11. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995;25:1034-41.
12. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA 2003;289:2560-71.
13. Christensen KL, Mulvany MJ. Location of resistance arteries. J Vasc Res 2001;38:1-12.
14. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary artery disease. Part 2. Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-39.
15. Conroy RM, Pyöräla K, Fitzgerald AP, et al., on behalf of the SCORE Project Group. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003:24;987-1003.
16. Cushman WC, Materson BJ, Williams DW, et al. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001;38:953-7.
17. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
18. De Cesaris R, Ranieri G, Filitti V, et al. Large artery compliance in essential hypertension. Effects of calcium antagonism and beta-blocking. Am J Hypertens 1992;5:624-8.
19. De Cesaris R, Ranieri G, Filitti V, et al. Forearm distensibility in patients with hypertension: comparative effects of long-term ACE-inhibition and beta-blocking. Clin Pharmacol Ther 1993;53:360-7.
20. De Luca N, Rosiello G, Lamenza F, et al. Reversal of cardiac and large artery structural abnormalities induced by long term anti-hypertensive treatment with trandolapril. Am J Cardiol 1992;70:52D-9D.
21. Deng LY, Li JS, Schiffrin EL. Endothelium-dependent relaxation of small arteries from essential hypertensive patients. Clin Sci 1995;88:611-22.
22. Domanski M, Mitchell G, Pfeffer M, et al. Pulse pressure and cardiovascular disease-related mortality. Follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002;287:2677-83.
23. Duprez DA, DuBuyzere ML, Reitzchel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-6.
24. Fagard RH, Pardaens K, Staessen JA, et al. The pulse pressure-to-stroke index ratio predicts cardiovascular events and death in uncomplicated hypertension. J Am Coll Cardiol 2001;38:227-31.
25. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:308-15.
26. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle aged and elderly US hypertensives. Analysis based on National Health and Nutrition Examination Survey (NHANES III). Hypertension 1998;37:869-74.
27. Franklin SS, Larson M, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-9.
28. Gasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a metaanalysis of clinical trial control groups. J Hypertens 2002;20:145-51.
29. Gerdts E, Papademetriou V, Calmieri V, et al. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Study). Am J Cardiol 2002;89:399-402.
30. Girerd X, Giannattasio C, Moulin C, et al. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatments in elderly patients. J Am Coll Cardiol 1998;31:1064-73.
31. Greene AS, Tonellato PJ, Lui J, et al. Microvascular rarefication and tissue vascular resistance in hypertension. Am J Physiol 1989;256:H126-31.
32. Griffin SA, Brown WCB, MacPherson F, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17:626-35.
33. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
34. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
35. Heesen WF, Beltmann FW, Smit AJ, et al. Effect of quinapril and triamterene/hydrochlorothiazide on cardiac and vascular end-organ damage in isolated systolic hypertension. J Cardiovasc Pharmacol 1998;31:187-94.
36. Intengan HD, Deng IY, Li JS, et al. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 1999;33:366-72.
37. Intengan HD, Thibault G, Li JS, et al. Resistance artery mechanics, structure and extracellular components in spontaneously hypertensive rats effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999;100:2267-75.
38. Karpanou E, Vyssoulis G, Daskalova D, et al. Differential effect of antihypertensive drugs on pulse pressure. Eur Heart J 2002;4: Suppl:208.abstract
39. Khder Y, Bray des Boscs L, el Ghawi R, et al. Calcium antagonists and thiazide diuretics have opposite effects on blood rheology and radial artery compliance in arterial hypertension. Fundam Clin Pharmacol 1998;12:457-62.
40. Klemsdahl TO, Moan A, Kjeldsen SE. Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension. Blood Press 1999;8:214-9.
41. Kool MJ, Lustermans FA, Breed JG, et al. Effect of perindopril and amiloride/hydrochlorothiazide on haemodynamic and vessel wall properties of large arteries. J Hypertens 1993;11:S362-3.
42. Lagrue G, Ansquer JC, Meyer-Heine A. Peripheral action of spironolactone: improvement in arterial elasticity. Am J Cardiol 1990;65:9K-11K.
43. Levenson J, Gariepy J, Megnien I, et al. Diuretics and arteriolar resistance and arterial compliance in human hypertension. Eur Heart J 1992;13:Suppl G:S48-52.
44. Levy BI, Ambrosio G, Pries AR, et al. Microcirculation in hypertension: a new target for treatment? Circulation 2001;104:735-40.
45. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998;16:1823-9.
46. London GM. Large artery function and alterations in hypertension. J Hypertens 1995;13:Suppl 2:35-8.
47. Mahmud A, Feely J. Favorable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens 2000;14:541-6.
48. Mancia G, Parati G, Hennig M et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 1989;19:1981-9.
49. Miettinen H, Haffner SM, Letho S, et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in non-diabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033-9.
50. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999;17:1065-72.
51. Nichols WW, O'Rourke M. McConald's blood flow in arteries: theoretical, experimental and clinical principles, 4th edn. London: Arnold, 1998:54-401.
52. O'Callaghan CJ, Williams B. The regulation of human vascular smooth muscle extracellular matrix protein production by alpha and beta adrenoreceptor stimulation. J Hypertens 2002;20:287-94.
53. Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT1 receptor antagonist losartan in essential hypertension. JRAAS 2000;1:40-5.
54. Park JB, Touyz RM, Chen JX, et al. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke prone SHR. Am J Hypertens 2002;15:78-84.
55. Perret F, Mooser V, Hayoz D, et al. Evaluation of arterial compliance-pressure curves. Effect of antihypertensive drugs. Hypertension 1991;18:Suppl 4:1177-83.
56. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure, determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160:1085-9.
57. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;10:363-9.
58. Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 1988;77:504-14.
59. Salar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003;107:2864-9.
60. Schartl M, Boksch, WG, Dreysse S, et al. Remodeling of myocardium and arteries by chronic angiotensin converting enzyme inhibition in hypertensive patients. J Hypertens 1994;12:Suppl 4:37-42.
61. Schiffrin EL. Effect of antihypertensive treatment on small artery remodeling in hypertension. Can J Physiol Pharmacol 2003;81:168-76.
62. Schiffrin EL, Deng LY. Comparison of effects of angiotensin converting enzyme inhibition and beta blockade on function of small arteries from hypertensive patients. Hypertension 1995;25:699-703.
63. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a b-blocker or a calcium channel antagonist. J Hypertens 1996;14:1247-55.
64. Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin antagonist losartan. Circulation 2000;101:1653-9.
65. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002;20:71-8.
66. Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens 2002;15:105-10.
67. Schmieder RE, Handrock R. Pulse pressure of German VALUE patients after 24 month. Dtsch Med Wochenschrift 2002;8:Suppl 1:8.
68. Scholze J, Hrsg. Hypertonie. Risikokonstellationen & Begleitkrankheiten. Praxisnahe Diagnostik und Individualtherapie. Berlin-Wien: Blackwell Wissenschaft, 1999.
69. Scholze J, Bida M, Juncken D, et al. Fixed-dose combinaton (ramipril-felodipine ER) in the first line therapy of essential hypertension ("IndComb"-Study). Dtsch Med Wochenschr 2003;128:Suppl 3:149-84.
70. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
71. Shimamoto H, Shimamoto Y. Lisinopril improves aortic compliance and renal flow: comparison with nifedipine. Hypertension 1995;25:327-34.
72. Shiragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000;35:1074-7.
73. Sihm I, Schroeder AP, Aalkjaer C, et al. Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. Am J Hypertens 1998;11:263-7.
74. Staessen JA, Amery A, Fagard R, et al. Isolated systolic hypertension in the elderly [Editorial Review]. J Hypertens 1990;9:393-405.
75. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
76. Taddei S, Virdis A, Ghiadoni L, et al. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997;30:1606-12.
77. Tavli T, Kozan O, Cin VG, et al. The effect of nisoldipine on carotid artery stiffness and left ventricular functions. Jpn Heart J 1995;36:629-37.
78. Thybo NK, Cooper N, Aalkjaer C, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25:474-81.
79. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000;52:639-72.
80. Trotta R, Dicastelnuovo A, De Luca N, et al. Pulse pressure is strongly associated with non-responder status to antihypertensive treatment. J Hypertens 2003;21:Suppl 4:S224.
81. Van Bortel LM, Kool Boudier HAS. Effects of antihypertensive agents on local arterial distensibility and compliance. Hypertension 1995;26:531-4.
82. Van Bortel LM, Struijker-Boudier HAJ, Safar ME. Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension 2001;38:914-21.
83. Van Merode T, van Bortel LM, Smeets Fa, et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens 1989;7:S262-3.
84. Verdecchia P, Schillaci G, Reboldi G, et al. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001;103:2579-84.
85. Virdis A, Ghiadoni L, Sudano I, et al. Effects of antihypertensive drugs on endothelial function in humans. J Hypertens 1998;16:Suppl 8:S103-10.
86. Winer N, Weber MA, Sowers JR. The effect of antihypertensive drugs on vascular compliance. Curr Hypertens Rep 2001;3:297-304.
87. Wu L, Iwai M, Nakagami H, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2002;104:2716-21.
88. Zanchetti A, Agabiti R, Dal Palú C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998;16:1667-76.
89. Zanchetti A, Hansson L, Dahlöf B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001;19:1149-59.